Navigation Links
SenesTech, Inc. Initiates Research Field Trials for ContraPest(R) in Indonesia
Date:10/24/2008

FLAGSTAFF, Ariz., Oct. 24 /PRNewswire/ -- SenesTech, Inc. has initiated field trials of its platform technology on the Indonesian island of Java in continuing research collaboration with international partners.

After meeting with Dr. Grant Singleton of the International Rice Research Institute in Manila, Philippines, Drs. Loretta Mayer and Cheryl Dyer of SenesTech, Inc. will join Dr. Lyn Hinds of the Australian Commonwealth Scientific and Industrial Research Organisation (CSIRO) and Dr. Sudarmaji of the Indonesian Rice Research Council (IRRC) at the field testing site of the IRRC in Sukamundi, Java. The group will initiate the first field trials of the active ingredient in ContraPest(R). This 21st century alternative to rat poison will be used to cause permanent reproductive failure in female rice field rats (Rattus argentiventer).

The environmentally neutral active ingredient in ContraPest(R) targets the ovaries of female rats, and selectively destroys early-stage egg cells. When these cells become inactive after exposure to ContraPest(R), they cannot mature, the animal can no longer ovulate, and the effect on rodent pest populations can be dramatic. These rodent pests can eat or damage up to 50% of a rice crop in Southeast Asia. Just a 10% increase in crop yield due to less rodent damage will result in feeding up to 380 million more people per year.

"Field testing in the agricultural environment where ContraPest(R) will be applied is a significant step forward in our product development process," said Everett Hale, CEO of SenesTech, Inc. "Collecting data from the rice fields on our first target species gives us the right information to design the best product possible."

Field trials with the rice fields on Java coincide with the annual rice planting and harvesting cycles. SenesTech, Inc. and its partners are planning more field testing in March and April 2009.

For additional information contact Everett Hale at ehale@senestech.com or visit http://www.SenesTech.com. ContraPest(TM) is projected to be available for commercial use in the spring of 2010.

ABOUT:(SenesTech, Inc.) SenesTech is a platform technology company located in Flagstaff, Arizona specializing in fertility control products for companion animals and wildlife population control.


'/>"/>
SOURCE SenesTech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Arizona-Based SenesTech, Inc., Partners With Australia to Stop Starvation Due to Rice Shortages
2. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
3. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
4. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
5. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
6. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
7. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
8. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
9. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
10. NeoStem Expands Adult Stem Cell Collection Network, Gains Footprint in Key Los Angeles Market and Initiates Waitlist
11. Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life Sciences , ... life sciences and healthcare industries, announces a presentation by Subbu Viswanathan and Jennifer ... “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach to ...
(Date:10/9/2017)... Oct. 9, 2017  BioTech Holdings announced today ... which its ProCell stem cell therapy prevents limb ... The Company, demonstrated that treatment with ProCell resulted ... saved as compared to standard bone marrow stem ... resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board meeting ... a professor in Harvard University’s Departments of Physics and Astronomy, has been selected for ... of the winning team for the 2015 Breakthrough Prize in Fundamental physics for the ...
(Date:10/9/2017)... , ... October 09, 2017 ... ... on October 5, 2017, in the medical journal, Epilepsia, Brain Sentinel’s SPEAC® ... gold standard, video EEG, in detecting generalized tonic-clonic seizures (GTCS) using surface ...
Breaking Biology Technology:
(Date:6/23/2017)... N.Y. and ITHACA, N.Y. ... ) and Cornell University, a leader in dairy research, ... with bioinformatics designed to help reduce the chances that ... With the onset of this dairy project, Cornell University ... Consortium for Sequencing the Food Supply Chain, a food ...
(Date:5/23/2017)... the first robotic gym for the rehabilitation and functional motor sense evaluation ... Genoa, Italy . The first 30 robots will be available from ... . The technology was developed and patented at the IIT laboratories ... Technology thanks to a 10 million euro investment from entrepreneur Sergio Dompè. ... ...
(Date:5/16/2017)... May 16, 2017   Bridge Patient Portal ... and MD EMR Systems , an electronic ... for GE, have established a partnership to build ... and the GE Centricity™ products, including Centricity Practice ... These new integrations will allow healthcare ...
Breaking Biology News(10 mins):